<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282178</url>
  </required_header>
  <id_info>
    <org_study_id>D2452L00007</org_study_id>
    <nct_id>NCT00282178</nct_id>
  </id_info>
  <brief_title>Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo</brief_title>
  <official_title>A 36 Week Three-Center Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Umeå University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sahlgrenska University Hospital, Sweden</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Umeå University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of a 12-week candesartan treatment
      compared with hydrochlorothiazide on insulin sensitivity assessed with hyperinsulinemic
      euglycemic clamp.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To investigate the mechanisms underlaying the diabetes-preventing effect of candesartan with
      respect to possible impact on insulin sensitivity, beta cell function and adipose tissue
      function and distribution. For this purpose comparisons will be performed with
      hydrochlorothiazide and placebo treatment. It is hypothesized that candesartan will improve
      insulin sensitivity as compared to hydrochlorothiazide and possibly also in comparison with
      placebo and that this could be explained by altered fat tissue function or distribution or by
      an altered sympathetic to parasympathetic balance in the autonomic nervous system.
      Hydrochlorthiazide is chosen as comparator because thiazides are a recommended firs-line
      therapy in hypertension. This drug class has some detrimental effects on glucose tolerance
      and in insulin sensitivity.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">April 2006</completion_date>
  <primary_completion_date type="Actual">March 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the effect of candesartan and hydorclorothiszide treatment on insulin sensitivity assessed with hyperinsulinemic euglycemic clamp</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare the effect of candesartan treatment with placebo on insulin sensitivity and compared with hydrochlorothiazide and placebo on:</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>beta cell function</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>vascular/endothelial function;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lipolysis regulation</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>autonomic nerve activity;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>abdominal fat tissue distribution;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>amount of lean body and fat mass;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>liver and muscle fat;</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>interaction betw. insulin and AT-II in fat cell metabolism; fat cell gene expression</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adipokine levels</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Hypertension</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Candesartan 16-32 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydrochlorothiazide 25-50 mg once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydrochlorothiazide</intervention_name>
    <description>25-50 mg once daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Once daily</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Candesartan</intervention_name>
    <description>16-32 mg once daily 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male and female 18-70 years old

          -  Diagnosed hypertension and abdominal obesity (waist circumference greater than or
             equal to 102 cm (M) or 88 cm (F)

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Treatment with more than two concomitant antihypertensive medications

          -  Diabetes Mellitus

          -  Other endocrine disorder

          -  Severe liver disease

          -  Severely reduced renal function

          -  Malignant disease

          -  Alcohol or drug abuse

          -  Severe psychiatric illness

          -  History of stroke, myocardial infarction, unstable angina pectoris, participation in
             another clinical trial less than two months prior to screening visit

          -  treatment with anti-obesity drugs

          -  anti-inflammatory drugs or immunosuppressive drugs
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Eriksson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept of Medicine, Umeå University Hospital, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <zip>SE-90185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 24, 2006</study_first_submitted>
  <study_first_submitted_qc>January 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 25, 2006</study_first_posted>
  <last_update_submitted>October 15, 2008</last_update_submitted>
  <last_update_submitted_qc>October 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Jan Eriksson</name_title>
    <organization>Umeå University Hospital</organization>
  </responsible_party>
  <keyword>Metabolic</keyword>
  <keyword>Hypertension</keyword>
  <keyword>Abdominal obesity</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Hyperinsulinemic euglycemic clamp</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
    <mesh_term>Hydrochlorothiazide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

